米非司酮治疗子宫肌瘤48例临床观察

A Clinical Study of 48 Cases Reports on Mifepristone Treating Uterine Leimyoma

目的:观察米非司酮治疗子宫肌瘤的临床效果。方法:将48例子宫肌瘤患者进行药物治疗,口服米非司酮12.5mg,每日1次连服3个月为一疗程,应用彩色超声监测治疗前后子宫肌瘤的变化,测定血清激素水平、肝肾功能、血红蛋白,观察服药后的副反应。结果:48例患者治疗期间均出现闭经,血红蛋白上升。治疗后血E_2、P平均水平较治疗前下降(P<0.01)。子宫及子宫肌瘤平均体积缩小,缩小率分别为30.1％和38.2％,治疗前后差异有显著性(P<0.01)。停药后62.5％患者子宫肌瘤逐渐增大。35％出现潮热、恶心等轻微副作用。结论:米非司酮治疗子宫肌瘤安全有效,但停药后易复发。

Objective: To investigate the effects of mifepristone treating uterine leiomyoma. Methods: 48 cases who had uterine leiomyomatosis took mifepristone 12. 5mg once a day lasting for 3 months. To observed change of uterine leiomyoma pre -treatment and post - treatment by color ultrasound and measured serous hormone levels, liver and renal function, and hemoglo-bin, meanwhile, the side effects of drugs were assessed. Results: 48 patients were amenorrhea with hemoglobin increasing during treatment. The mean level of serous Estrogen and progesterone dropped after treatment( P <0. 01). The percentage of the mean cubage of uterus and uterine leimoyoma diminished 30. 1% and 38. 2% and there was no significant difference be-tween pre - treatment and post - treatment ( P <0.01). The volume of leiomyoma increased among 62. 5% patients after stop-ping treatment. The side effects such as flash and nausea appeared among 35% patients. Conclusion: Mifepristone is a safe and effective drug in treating uterine leiomyoma, but the clinical symptoms are easy to recur after stopping treatment.